These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21885288)

  • 21. DP(2) receptor antagonists in development.
    Norman P
    Expert Opin Investig Drugs; 2010 Aug; 19(8):947-61. PubMed ID: 20615077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of prostaglandin D2 receptor antagonists based on a tetrahydropyridoindole scaffold.
    Beaulieu C; Guay D; Wang Z; Leblanc Y; Roy P; Dufresne C; Zamboni R; Berthelette C; Day S; Tsou N; Denis D; Greig G; Mathieu MC; O'Neill G
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2696-700. PubMed ID: 18359630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching between agonists and antagonists at CRTh2 in a series of highly potent and selective biaryl phenoxyacetic acids.
    Luker T; Bonnert R; Schmidt J; Sargent C; Paine SW; Thom S; Pairaudeau G; Patel A; Mohammed R; Akam E; Dougall I; Davis AM; Abbott P; Brough S; Millichip I; McInally T
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3616-21. PubMed ID: 21592791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).
    Sturino CF; O'Neill G; Lachance N; Boyd M; Berthelette C; Labelle M; Li L; Roy B; Scheigetz J; Tsou N; Aubin Y; Bateman KP; Chauret N; Day SH; Lévesque JF; Seto C; Silva JH; Trimble LA; Carriere MC; Denis D; Greig G; Kargman S; Lamontagne S; Mathieu MC; Sawyer N; Slipetz D; Abraham WM; Jones T; McAuliffe M; Piechuta H; Nicoll-Griffith DA; Wang Z; Zamboni R; Young RN; Metters KM
    J Med Chem; 2007 Feb; 50(4):794-806. PubMed ID: 17300164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isoquinoline derivatives as potent CRTH2 receptor antagonists: synthesis and SAR.
    Nishikawa-Shimono R; Sekiguchi Y; Koami T; Kawamura M; Wakasugi D; Watanabe K; Wakahara S; Matsumoto K; Takayama T
    Bioorg Med Chem Lett; 2012 May; 22(9):3305-10. PubMed ID: 22469703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benzimidazoles as new potent and selective DP antagonists for the treatment of allergic rhinitis.
    Beaulieu C; Wang Z; Denis D; Greig G; Lamontagne S; O'Neill G; Slipetz D; Wang J
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3195-9. PubMed ID: 15149674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective delta agonist (+)-4-[(alpha R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]- N,N-diethylbenzamide (SNC 80) and related novel nonpeptide delta opioid receptor ligands.
    Calderon SN; Rice KC; Rothman RB; Porreca F; Flippen-Anderson JL; Kayakiri H; Xu H; Becketts K; Smith LE; Bilsky EJ; Davis P; Horvath R
    J Med Chem; 1997 Feb; 40(5):695-704. PubMed ID: 9057856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and synthesis of an orally active matrix metalloproteinase inhibitor.
    Yamamoto S; Nakatani S; Ikura M; Sugiura T; Nishita Y; Itadani S; Ogawa K; Ohno H; Takahashi K; Nakai H; Toda M
    Bioorg Med Chem; 2006 Sep; 14(18):6383-403. PubMed ID: 16765051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pyrrolidin-3-yl-N-methylbenzamides as potent histamine 3 receptor antagonists.
    Zhou D; Gross JL; Sze JY; Adedoyin AB; Bowlby M; Di L; Platt BJ; Zhang G; Brandon N; Comery TA; Robichaud AJ
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5957-60. PubMed ID: 21843941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Azaindoles as potent CRTH2 receptor antagonists.
    Simard D; Leblanc Y; Berthelette C; Zaghdane MH; Molinaro C; Wang Z; Gallant M; Lau S; Thao T; Hamel M; Stocco R; Sawyer N; Sillaots S; Gervais F; Houle R; Lévesque JF
    Bioorg Med Chem Lett; 2011 Jan; 21(2):841-5. PubMed ID: 21185722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Arginine binding motifs: design and synthesis of galactose-derived arginine tweezers as galectin-3 inhibitors.
    Oberg CT; Leffler H; Nilsson UJ
    J Med Chem; 2008 Apr; 51(7):2297-301. PubMed ID: 18318467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel CRTH2 antagonists: a review of patents from 2006 to 2009.
    Ulven T; Kostenis E
    Expert Opin Ther Pat; 2010 Nov; 20(11):1505-30. PubMed ID: 20946089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis, and structure-activity relationships of 1-,3-,8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor.
    Carotti A; Cadavid MI; Centeno NB; Esteve C; Loza MI; Martinez A; Nieto R; Raviña E; Sanz F; Segarra V; Sotelo E; Stefanachi A; Vidal B
    J Med Chem; 2006 Jan; 49(1):282-99. PubMed ID: 16392813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.
    Tsukamoto I; Koshio H; Kuramochi T; Saitoh C; Yanai-Inamura H; Kitada-Nozawa C; Yamamoto E; Yatsu T; Shimada Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2009 Apr; 17(8):3130-41. PubMed ID: 19321349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N1-Benzoyl-N2-[1-(1-naphthyl)ethyl]-trans-1,2-diaminocyclohexanes: Development of 4-chlorophenylcarboxamide (calhex 231) as a new calcium sensing receptor ligand demonstrating potent calcilytic activity.
    Kessler A; Faure H; Petrel C; Rognan D; Césario M; Ruat M; Dauban P; Dodd RH
    J Med Chem; 2006 Aug; 49(17):5119-28. PubMed ID: 16913701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists.
    Sandham DA; Aldcroft C; Baettig U; Barker L; Beer D; Bhalay G; Brown Z; Dubois G; Budd D; Bidlake L; Campbell E; Cox B; Everatt B; Harrison D; Leblanc CJ; Manini J; Profit R; Stringer R; Thompson KS; Turner KL; Tweed MF; Walker C; Watson SJ; Whitebread S; Willis J; Williams G; Wilson C
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4347-50. PubMed ID: 17531480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits.
    Ulven T; Receveur JM; Grimstrup M; Rist Ø; Frimurer TM; Gerlach LO; Mathiesen JM; Kostenis E; Uller L; Högberg T
    J Med Chem; 2006 Nov; 49(23):6638-41. PubMed ID: 17154491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.
    Ohmori J; Maeno K; Hidaka K; Nakato K; Matsumoto M; Tada S; Hattori H; Sakamoto S; Tsukamoto S; Usuda S; Mase T
    J Med Chem; 1996 Jul; 39(14):2764-72. PubMed ID: 8709107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GRID/GOLPE 3D quantitative structure-activity relationship study on a set of benzamides and naphthamides, with affinity for the dopamine D3 receptor subtype.
    Nilsson J; Wikström H; Smilde A; Glase S; Pugsley T; Cruciani G; Pastor M; Clementi S
    J Med Chem; 1997 Mar; 40(6):833-40. PubMed ID: 9083471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.